Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year. Tirzepatide ...

Eli Lilly is paying up to $630m for a Phase I metabolic-associated ... The drugmaker’s blockbuster GLP-1RA drug tirzepatide – ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been making waves in the biopharmaceutical industry with its strong portfolio of ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Eli Lilly is paying up to $630m for a Phase I ... The drugmaker’s blockbuster GLP-1RA drug tirzepatide – the active ingredient in Mounjaro and Zepbound – is being investigated as a treatment ...